Aptevo Therapeutics Inc. found using ticker (APVO) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 69 and 64 calculating the mean target price we have 65.67. With the stocks previous close at 36.17 this would imply there is a potential upside of 81.6%. The 50 day moving average now sits at 40.17 and the 200 day MA is 18.72. The company has a market capitalisation of $154m. Company Website: http://aptevotherapeutics.com
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company’s preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.